You are using an outdated browser. Please upgrade your browser to improve your experience.


Ligand Summary
The precise mechanism by which ocrelizumab exerts its therapeutic effects in multiple sclerosis is unknown, but is presumed to involve binding to CD20, a cell surface antigen present on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, ocrelizumab results in antibody-dependent cellular cytolysis and complement-mediated lysis.
Synonyms & Links
DrugCentral: 5223
LyCHI:  ocrelizumab

Target Activities